Curesponse is a clinical-stage cancer diagnostics company developing a three-dimensional tissue culture system for modeling cancer growth and drug response. The platform preserves the cancer tissue architecture, including vasculature and immune system, accurately reflecting the cancer growth found in the body.

The company is harnessing the technology to create a personalized cancer diagnostic assay that can be used to determine the drug response for a specific individual's tumor type. Patients and clinicians can send samples of their tumor to be tested with a panel of anticancer therapies predetermined by genomic screening and physician assessment.